백혈병 치료제 시장 보고서(2026년)

Leukemia therapeutics refer to treatments used to manage an aggressive, rapidly progressing cancer in which the blood or bone marrow contains an excessive number of myeloblasts, or immature white blood cells. The choice of treatment for leukemia depends on several factors, including the patient's age, overall health, the specific type of leukemia, its stage, and its location within the body.

The primary treatment approaches in leukemia therapeutics include chemotherapy, immunotherapy, targeted therapy, and other treatment options. Immunotherapy is a treatment strategy that enhances the body's immune system to identify and destroy cancerous cells. These therapies are used to treat acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and other forms of leukemia, utilizing both small-molecule drugs and biologics. Leukemia therapeutics are administered across various end-user settings, including hospitals, homecare environments, specialty clinics, and other healthcare facilities.

Tariffs have influenced the leukemia therapeutics market by increasing the cost of imported active pharmaceutical ingredients (APIs), laboratory equipment, and biologics production materials. This impact is most significant in regions reliant on international supply chains, such as Asia-Pacific and parts of Europe. Segments like targeted therapy, biologics, and CAR T-cell therapy are particularly affected due to the high-cost components. While tariffs may increase production costs, they also encourage local manufacturing and innovation, leading to potential self-reliance and development of cost-optimized treatment solutions.

The leukemia therapeutics market research report is one of a series of new reports from The Business Research Company that provides leukemia therapeutics market statistics, including leukemia therapeutics industry global market size, regional shares, competitors with a leukemia therapeutics market share, detailed leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the leukemia therapeutics industry. This leukemia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The leukemia therapeutics market size has grown strongly in recent years. It will grow from $18.67 billion in 2025 to $20.14 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising leukemia incidence rates, development of first-generation chemotherapy drugs, increased healthcare expenditure in developed regions, advancements in bone marrow transplantation, growth in biologics research.

The leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $27.41 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to expansion of CAR T-cell therapies, adoption of precision medicine approaches, integration of AI in treatment planning, growth in homecare treatment solutions, development of novel targeted therapies. Major trends in the forecast period include personalized leukemia treatment, advanced diagnostic integration, outpatient and home-based therapy expansion, combination therapy development, rare and resistant leukemia focus.

The increasing prevalence of leukemia is contributing to the growth of the leukemia therapeutics market. Leukemia is a form of blood cancer that originates in the bone marrow and leads to uncontrolled production of abnormal blood cells. Improved access to medical care for leukemia patients worldwide, along with the expanding availability of treatment options, has increased the demand for leukemia therapies. For example, in January 2023, the American Cancer Society, a US-based health organization, reported that approximately 59,610 new cases of leukemia of all types and about 23,710 deaths related to leukemia were expected in the United States in 2023. In addition, an estimated 20,380 new cases of acute myeloid leukemia (AML) and around 11,310 deaths associated with AML were projected for the same year. As a result, the rising incidence of leukemia is supporting the growth of the leukemia therapeutics market.

Major companies operating in the leukemia therapeutics market are focusing on the development of innovative treatments, such as CAR T-cell therapies, to expand their customer base, boost sales, and increase revenue. Chimeric Antigen Receptor T-cell (CAR-T) therapy is an advanced form of immunotherapy used to treat certain types of cancer. For example, in March 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) had approved Breyanzi (lisocabtagene maraleucel; liso-cel). This therapy is a CD19-directed CAR T-cell treatment intended for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma-2 (BCL-2) inhibitor.

In February 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. This acquisition strengthens AstraZeneca's growing cell therapy pipeline through the addition of GC012F, a novel clinical-stage FasTCAR-enabled autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets both BCMA and CD19. Following the acquisition, Gracell will operate as a wholly owned subsidiary of AstraZeneca, continuing its activities in both China and the United States. Gracell Biotechnologies Inc. is a China-based biopharmaceutical company focused on the development of cell therapies for leukemia and autoimmune disorders.

Major companies operating in the leukemia therapeutics market are Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.

North America was the largest region in the leukemia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the leukemia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leukemia therapeutics market includes revenues earned by entities by killing fast-growing cancer cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Leukemia Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses leukemia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for leukemia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The leukemia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Treatment Type: Chemotherapy; Immunotherapy; Targeted Therapy; Other Treatments
• 2) By Type Of Leukemia: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Other Type Of Leukemia
• 3) By Molecule Type: Small Molecules; Biologics
• 4) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Chemotherapy: Alkylating Agents; Antimetabolites; Plant Alkaloids; Corticosteroids
• 2) By Immunotherapy: Monoclonal Antibodies; CAR T-Cell Therapy; Immune Checkpoint Inhibitors; Vaccines
• 3) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); BCL-2 Inhibitors; IDH Inhibitors; Other Targeted Agents
• 4) By Other Treatments: Radiation Therapy; Stem Cell Transplantation; Supportive Care Treatments
• Companies Mentioned: Novartis International AG; AbbVie Inc.; Bristol Myers Squibb Company; F. Hoffmann-La Roche AG; Sanofi S. A.; Agios Pharmaceuticals; Amgen Inc.; Argenx SE; Astellas Pharma Inc.; BioLineRx Ltd.; Cellerant Therapeutics Inc.; Daiichi Sankyo Company Limited; Forma Therapeutics Inc.; Gilead Sciences Inc.; Incyte Corporation; Jazz Pharmaceuticals plc; Johnson & Johnson; Mirati Therapeutics Inc.; Molecular Templates Inc.; Ono Pharmaceutical Co. Ltd.; Pfizer Inc.; Seattle Genetics Inc.; Stemline Therapeutics Inc.; Sunesis Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; TG Therapeutics Inc.; Allogene Therapeutics Inc.; Blueprint Medicines Corporation; Karyopharm Therapeutics Inc.; Verastem Oncology Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Leukemia Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Leukemia Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Leukemia Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Leukemia Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Personalized Leukemia Treatment
  • 4.2.2 Advanced Diagnostic Integration
  • 4.2.3 Outpatient And Home-Based Therapy Expansion
  • 4.2.4 Combination Therapy Development
  • 4.2.5 Rare And Resistant Leukemia Focus

5. Leukemia Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Homecare Providers
• 5.4 Cancer Research Centers
• 5.5 Oncology Institutes

6. Leukemia Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Leukemia Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Leukemia Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Leukemia Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Leukemia Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Leukemia Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Leukemia Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Leukemia Therapeutics Market Segmentation

• 9.1. Global Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments
• 9.2. Global Leukemia Therapeutics Market, Segmentation By Type Of Leukemia, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia
• 9.3. Global Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecules, Biologics
• 9.4. Global Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End-Users
• 9.5. Global Leukemia Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Alkylating Agents, Antimetabolites, Plant Alkaloids, Corticosteroids
• 9.6. Global Leukemia Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibodies, CAR T-Cell Therapy, Immune Checkpoint Inhibitors, Vaccines
• 9.7. Global Leukemia Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tyrosine Kinase Inhibitors (TKIs), BCL-2 Inhibitors, IDH Inhibitors, Other Targeted Agents
• 9.8. Global Leukemia Therapeutics Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Radiation Therapy, Stem Cell Transplantation, Supportive Care Treatments

10. Leukemia Therapeutics Market Regional And Country Analysis

• 10.1. Global Leukemia Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Leukemia Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Leukemia Therapeutics Market

• 11.1. Asia-Pacific Leukemia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Leukemia Therapeutics Market

• 12.1. China Leukemia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Leukemia Therapeutics Market

• 13.1. India Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Leukemia Therapeutics Market

• 14.1. Japan Leukemia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Leukemia Therapeutics Market

• 15.1. Australia Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Leukemia Therapeutics Market

• 16.1. Indonesia Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Leukemia Therapeutics Market

• 17.1. South Korea Leukemia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Leukemia Therapeutics Market

• 18.1. Taiwan Leukemia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Leukemia Therapeutics Market

• 19.1. South East Asia Leukemia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Leukemia Therapeutics Market

• 20.1. Western Europe Leukemia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Leukemia Therapeutics Market

• 21.1. UK Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Leukemia Therapeutics Market

• 22.1. Germany Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Leukemia Therapeutics Market

• 23.1. France Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Leukemia Therapeutics Market

• 24.1. Italy Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Leukemia Therapeutics Market

• 25.1. Spain Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Leukemia Therapeutics Market

• 26.1. Eastern Europe Leukemia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Leukemia Therapeutics Market

• 27.1. Russia Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Leukemia Therapeutics Market

• 28.1. North America Leukemia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Leukemia Therapeutics Market

• 29.1. USA Leukemia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Leukemia Therapeutics Market

• 30.1. Canada Leukemia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Leukemia Therapeutics Market

• 31.1. South America Leukemia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Leukemia Therapeutics Market

• 32.1. Brazil Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Leukemia Therapeutics Market

• 33.1. Middle East Leukemia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Leukemia Therapeutics Market

• 34.1. Africa Leukemia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Leukemia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Type Of Leukemia, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Leukemia Therapeutics Market Regulatory and Investment Landscape

36. Leukemia Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Leukemia Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Leukemia Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Leukemia Therapeutics Market Company Profiles
  • 36.3.1. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sanofi S. A. Overview, Products and Services, Strategy and Financial Analysis

37. Leukemia Therapeutics Market Other Major And Innovative Companies

• Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd.

38. Global Leukemia Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Leukemia Therapeutics Market

40. Leukemia Therapeutics Market High Potential Countries, Segments and Strategies

• 40.1 Leukemia Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Leukemia Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Leukemia Therapeutics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer